Weight & Metabolic Research Peptides
Reference standards for incretin and metabolic-pathway research, including the GLP-1 receptor agonist semaglutide, the dual GIP/GLP-1 agonist tirzepatide, and the triple-agonist retatrutide — alongside cagrilintide, AOD-9604, MOTS-c, tesamorelin, and 5-Amino-1MQ. These compounds are widely studied in appetite-regulation, energy-expenditure, and insulin-signaling models.
Every lot is supplied lyophilized in multi-vial research kits and ships from our US facility within 48 hours with tracking. For in-vitro laboratory research and analytical method development only — not for human or veterinary use.
GLP-1 receptor agonist studied for appetite suppression, reduced caloric intake, and metabolic regulation.
Dual GIP/GLP-1 receptor agonist. Studied for superior appetite reduction and weight management outcomes.
Triple agonist (GLP-1/GIP/Glucagon) under active research for metabolic and body composition outcomes.
Modified fragment of HGH studied for fat metabolism stimulation without influencing IGF-1.
Small molecule NNMT inhibitor studied for fat cell reduction and metabolic efficiency.
Dual-action amylin/GLP-1 combination. Studied for synergistic appetite and weight management.
Mitochondrial-derived peptide studied for metabolic regulation, insulin sensitivity, and exercise adaptation.
GHRH analog studied for visceral fat reduction and growth hormone pulse stimulation.